Search research articles
Contact Us
Filters
Showing results (51-60 of 60) with videos related to
Page
of 6
Sort By:
You have reached the last page of results.
This site can display upto 60 results.
Gynecologic Oncology
|
April 26, 2003
Stage IC adenocarcinoma of the endometrium: survival comparisons of surgically staged patients with and without adjuvant radiation therapy
J Michael Straughn, Warner K Huh, James W Orr, et al.
ACS Medicinal Chemistry Letters
|
December 18, 2020
Discovery of Highly Selective and Potent HDAC3 Inhibitors Based on a 2-Substituted Benzamide Zinc Binding Group
Jian Liu, Younong Yu, Joseph Kelly, et al.
Bioorganic & Medicinal Chemistry Letters
|
February 17, 2005
The synthesis of substituted bipiperidine amide compounds as CCR3 antagonists
Pauline C Ting, Joe F Lee, Jie Wu, et al.
Bioorganic & Medicinal Chemistry Letters
|
April 26, 2020
Discovery of ethyl ketone-based HDACs 1, 2, and 3 selective inhibitors for HIV latency reactivation
Wensheng Yu, Jian Liu, Younong Yu, et al.
ACS Medicinal Chemistry Letters
|
July 18, 2020
Selective Class I HDAC Inhibitors Based on Aryl Ketone Zinc Binding Induce HIV-1 Protein for Clearance
Jian Liu, Joseph Kelly, Wensheng Yu, et al.
Bioorganic & Medicinal Chemistry Letters
|
December 17, 2009
Non-aromatic A-ring replacement in the triaryl bis-sulfone CB2 receptor inhibitors
Eric J Gilbert, Guowei Zhou, Michael K C Wong, et al.
Lancet (London, England)
|
September 17, 2021
Daily testing for contacts of individuals with SARS-CoV-2 infection and attendance and SARS-CoV-2 transmission in English secondary schools and colleges: an open-label, cluster-randomised trial
Bernadette C Young, David W Eyre, Saroj Kendrick, et al.
Bioorganic & Medicinal Chemistry Letters
|
May 12, 2018
Discovery of 3(S)-thiomethyl pyrrolidine ERK inhibitors for oncology
Sobhana Babu Boga, Abdul-Basit Alhassan, Alan B Cooper, et al.
Bioorganic & Medicinal Chemistry Letters
|
August 3, 2020
Potent, non-covalent reversible BTK inhibitors with 8-amino-imidazo[1,5-a]pyrazine core featuring 3-position bicyclic ring substitutes
Jian Liu, Deodial Guiadeen, Arto Krikorian, et al.
ACS Medicinal Chemistry Letters
|
July 24, 2018
MK-8353: Discovery of an Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology
Sobhana Babu Boga, Yongqi Deng, Liang Zhu, et al.
Page
of 6
Search research articles
Search
Showing results (51-60 of 60) with videos related to
Sort By:
Page
of 6
You have reached the last page of results.
This site can display upto 60 results.
Gynecologic Oncology
|
April 26, 2003
Stage IC adenocarcinoma of the endometrium: survival comparisons of surgically staged patients with and without adjuvant radiation therapy
J Michael Straughn, Warner K Huh, James W Orr, et al.
ACS Medicinal Chemistry Letters
|
December 18, 2020
Discovery of Highly Selective and Potent HDAC3 Inhibitors Based on a 2-Substituted Benzamide Zinc Binding Group
Jian Liu, Younong Yu, Joseph Kelly, et al.
Bioorganic & Medicinal Chemistry Letters
|
February 17, 2005
The synthesis of substituted bipiperidine amide compounds as CCR3 antagonists
Pauline C Ting, Joe F Lee, Jie Wu, et al.
Bioorganic & Medicinal Chemistry Letters
|
April 26, 2020
Discovery of ethyl ketone-based HDACs 1, 2, and 3 selective inhibitors for HIV latency reactivation
Wensheng Yu, Jian Liu, Younong Yu, et al.
ACS Medicinal Chemistry Letters
|
July 18, 2020
Selective Class I HDAC Inhibitors Based on Aryl Ketone Zinc Binding Induce HIV-1 Protein for Clearance
Jian Liu, Joseph Kelly, Wensheng Yu, et al.
Bioorganic & Medicinal Chemistry Letters
|
December 17, 2009
Non-aromatic A-ring replacement in the triaryl bis-sulfone CB2 receptor inhibitors
Eric J Gilbert, Guowei Zhou, Michael K C Wong, et al.
Lancet (London, England)
|
September 17, 2021
Daily testing for contacts of individuals with SARS-CoV-2 infection and attendance and SARS-CoV-2 transmission in English secondary schools and colleges: an open-label, cluster-randomised trial
Bernadette C Young, David W Eyre, Saroj Kendrick, et al.
Bioorganic & Medicinal Chemistry Letters
|
May 12, 2018
Discovery of 3(S)-thiomethyl pyrrolidine ERK inhibitors for oncology
Sobhana Babu Boga, Abdul-Basit Alhassan, Alan B Cooper, et al.
Bioorganic & Medicinal Chemistry Letters
|
August 3, 2020
Potent, non-covalent reversible BTK inhibitors with 8-amino-imidazo[1,5-a]pyrazine core featuring 3-position bicyclic ring substitutes
Jian Liu, Deodial Guiadeen, Arto Krikorian, et al.
ACS Medicinal Chemistry Letters
|
July 24, 2018
MK-8353: Discovery of an Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology
Sobhana Babu Boga, Yongqi Deng, Liang Zhu, et al.
Page
of 6